A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

DSpace/Manakin Repository

A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD

Show simple item record

dc.contributor.author Klint, Thorsten
dc.contributor.author Adler, Lenard
dc.contributor.author West, Scott
dc.contributor.author Wesnes, Keith
dc.contributor.author Graff, Ole
dc.contributor.author Mikkelsen, Birgit
dc.contributor.author Wilens, Timothy Edwin
dc.date.accessioned 2011-04-08T16:30:39Z
dc.date.issued 2008
dc.identifier.citation Wilens, Timothy E., Thorsten Klint, Lenard Adler, Scott West, Keith Wesnes, Ole Graff, and Birgit Mikkelsen. 2008. A randomized controlled trial of a novel mixed monoamine reuptake inhibitor in adults with ADHD. Behavioral and Brain Functions : BBF 4: 24. en_US
dc.identifier.issn 1744-9081 en_US
dc.identifier.uri http://nrs.harvard.edu/urn-3:HUL.InstRepos:4817628
dc.description.abstract Background: NS2359 is a potent reuptake blocker of noradrenalin, dopamine, and serotonin. The aim of the study was to investigate the efficacy, safety and cognitive function of NS2359 in adults with a DSM IV diagnosis of ADHD. Methods: The study was a multi-centre, double-blind, randomized placebo-controlled, parallel group design in outpatient adults (18–55 years) testing 0.5 mg NS2359 vs. placebo for 8 weeks. Multiple assessments including computerized neuropsychological evaluation were performed. Results: There was no significant difference between NS2359 (n = 63) versus placebo (n = 63) on the primary outcome measure reduction in investigator rated ADHD-RS total score (7.8 versus 6.4; p less than 0.45). However, in subjects with the inattentive subtype, there were significantly more responders in the NS2359 group compared to placebo (41% versus 7%; p less than 0.01). For all secondary variables (ADHD-RS patient rated; The Conners Adult ADHD Scale; The Brown Adult Scale, and CGI-improvement scale) there were no significant differences between the two groups; however, in the inattentive subgroup, the response to treatment was significantly larger than to placebo. NS2359 improved composite factor scores of attention, episodic- and working memory. No serious adverse events were reported with insomnia, headaches and loss of appetite most commonly reported as side effects. Conclusion: No overall effect of NS2359 was found on overall symptoms of ADHD. There was also a modest signal of improvement in the inattentive adults with ADHD and cognition warranting further exploration using differing doses. en_US
dc.language.iso en_US en_US
dc.publisher BioMed Central en_US
dc.relation.isversionof doi:10.1186/1744-9081-4-24 en_US
dc.relation.hasversion http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2442604/pdf/ en_US
dash.license LAA
dc.title A Randomized Controlled Trial of a Novel Mixed Monoamine Reuptake Inhibitor in Adults with ADHD en_US
dc.type Journal Article en_US
dc.description.version Version of Record en_US
dc.relation.journal Behavioral and Brain Functions : BBF en_US
dash.depositing.author Wilens, Timothy Edwin
dc.date.available 2011-04-08T16:30:39Z
dash.affiliation.other HMS^Psychiatry-Massachusetts General Hospital en_US

Files in this item

Files Size Format View
2442604.pdf 460.2Kb PDF View/Open

This item appears in the following Collection(s)

Show simple item record

 
 

Search DASH


Advanced Search
 
 

Submitters